Crucell Switzerland AG, a wholly-owned subsidiary of the Johnson & Johnson group of companies, has sold the oral typhoid vaccine Vivotif® as well as its manufacturing facility in Thoerishaus, near Berne, Switzerland, to PaxVax, Inc. together with marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Pestalozzi advised Crucell Switzerland on all Swiss legal and tax aspects of the transaction.